- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 59,48 | +0,41 % | Novonesis (Novozymes A/S): Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook | COPENHAGEN, Denmark - May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The... ► Artikel lesen | |
| GENMAB | 174,20 | +0,35 % | Genmab A/S: Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY) Development Program at the 2025 European Hematology Association (EHA) Congress | Data from 14 abstracts highlight the depth, breadth, and strength of Genmab's comprehensive epcoritamab development program across multiple patient populations and treatment settings Genmab... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,842 | -0,14 % | Arbutus Biopharma Corp - 10-Q, Quarterly Report | ||
| MOLECULIN BIOTECH | 0,920 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update | Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports... ► Artikel lesen | |
| VERICEL | 37,200 | -4,12 % | Vericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance | Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 MillionApproximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,297 | -2,30 % | Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress | - Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,754 | +11,21 % | MustGrow Biologics Corp.: MustGrow Adds New Biostimulants and Inoculants to Canadian Product Portfolio | Saskatoon, Saskatchewan--(Newsfile Corp. - April 1, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,365 | -100,00 % | BioXcel Therapeutics: Deutliche Verbesserung der Quartalszahlen trotz Umsatzrückgang | ||
| REGENXBIO | 7,500 | 0,00 % | REGENXBIO Inc.: REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II | FDA assigns PDUFA target action date of November 9, 2025
RGX-121 on track to be the first gene therapy and one-time treatment for MPS II
Partner Nippon Shinyaku... ► Artikel lesen | |
| AKEBIA | 2,200 | 0,00 % | Akebia projects Vafseo rollout to double patient access by Q4 2025 | ||
| FENNEC PHARMACEUTICALS | 5,750 | +0,88 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,300 | 0,00 % | Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views | ||
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 07.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 07.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 07.02.2025ISIN NameCA09226M1005 BLACK... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 3,520 | +8,31 % | Pre-market Movers: ZK International, Jade Biosciences, Twin Vee Powercats, Corvus Pharmaceuticals, Iovance Biotherapeutics | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green ZK International Group Co., Ltd. (ZKIN) is up over... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 8,500 | -2,30 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial ... ► Artikel lesen |
Das Unternehmen BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,006 (-0,48 %) liegt der Kurs bei 1,246 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.